Proteome Sciences is a London (UK) and Frankfurt (Germany) based SME with expertise in proteomics and biomarker research. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies.
Our PS Biomarker Services for discovery and validation of biomarkers includes gel-based and gel-free separations linked to tandem mass spectrometry. We use proprietary isobaric tagging for higher throughput and better precision in biomarker discovery. We have also developed identical isotopic tags for rapid development of biomarker validation assays using isotope dilution mass spectrometry and Selected Reaction Monitoring (SRM). Such MS-based assays are rapid to develop compared to immunoassay and have potential for high rates of multiplexing. Proteome Sciences also provides analysis of post-translational modifications (PTM) and assays for such PTMs.
We have wide experience across the life sciences sector working with many different human and animal sample types including blood plasma, CSF, solid tissues, cell culture material etc. As a reflection of the quality of our approach, the purpose built, state-of-the-art research facility in Frankfurt is certified to ISO 9001:2008.
Show moreProteome Sciences is headquartered in Cobham, GB
Report incorrect company information
Proteome Sciences Office Locations
Proteome Sciences has an office in Cobham
Cobham, GB (HQ)
Downside Bridge Rd Covenham House
Report incorrect company information
Proteome Sciences Financials and Metrics
Proteome Sciences Financials
Proteome Sciences's revenue was reported to be £2.74 m in FY, 2016 which is a 45.8% increase from the previous period.
| GBP | |
|---|---|
Revenue (FY, 2016) | 2.7 m |
Revenue growth (FY, 2015 - FY, 2016), % | 45.8% |
Gross profit (FY, 2016) | 1.5 m |
Gross profit margin (FY, 2016), % | 56.4% |
Net income (FY, 2016) | (2.3 m) |
EBITDA (FY, 2016) | (2.1 m) |
EBIT (FY, 2016) | (2.7 m) |
Market capitalization (31-Oct-2017) | 9.8 m |
Closing share price (31-Oct-2017) | 0 |
Cash (31-Dec-2016) | 2.9 m |
Proteome Sciences's current market capitalization is £9.8 m.
| GBP | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 266 k | 849.5 k | 1.3 m | 10 m | 1 m | 1.2 m | 2.1 m | 1.6 m | 1.9 m | 2.7 m |
Revenue growth, % | (27%) | 21% | 46% | |||||||
Cost of goods sold | 113 k | 225.9 k | 329 k | 105.1 k | 257.3 k | 385.5 k | 592.7 k | 605 k | 791 k | 1.2 m |
Gross profit | 153 k | 623.6 k | 976.7 k | 9.9 m | 763.9 k | 767.5 k | 1.5 m | 956 k | 1.1 m | 1.5 m |
| GBP | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 530 k | 273.8 k | 131.2 k | 9.5 m | 4.1 m | 858.2 k | 600.3 k | 1.9 m | 1.8 m | 2.9 m |
Accounts Receivable | 51 k | 89.3 k | 207 k | 364 k | 399 k | |||||
Inventories | 107 k | 188.1 k | 169.9 k | 209.3 k | 300.5 k | 331.4 k | 402.6 k | 344 k | 291 k | 600 k |
Current Assets | 1.2 m | 1.1 m | 995.9 k | 9.9 m | 5.3 m | 2.2 m | 1.8 m | 3.3 m | 3.4 m | 4.9 m |
| GBP | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (5.3 m) | (4.6 m) | (4 m) | 4.6 m | (4 m) | (4.3 m) | (3.1 m) | (3.6 m) | (2.7 m) | (2.3 m) |
Cash From Operating Activities | 4.1 m | (4.1 m) | (3 m) | 4 m | (5.2 m) | (3.4 m) | (2.8 m) | (3.3 m) | (2.4 m) | (2 m) |
Cash From Financing Activities | 4.3 m | 3.7 m | 2.7 m | 6.1 m | 23.9 k | 2.6 m | 4.8 m | 2.3 m | 2.9 m | |
Net Change in Cash | 196 k | (469.7 k) | (282.4 k) | 9.4 m | (5.3 m) | (3.3 m) | (218.3 k) | 1.4 m | (72 k) | 882 k |
| GBP | Y, 2016 |
|---|---|
Financial Leverage | -51.3 x |
Report incorrect company information
